Press Release5 Minute ReadDec | 3 | 2019
Susanne van Veluw, PhDIf we direct therapeutic strategies towards promoting healthy vasculature and therefore improve clearance of amyloid-beta from the brain, we may be able to prevent or delay the onset of Alzheimer’s disease in the future.”
BOSTON – In patients with Alzheimer’s disease, amyloid-beta protein fragments accumulate in the tissue and blood vessels of the brain, likely due to a faulty clearance mechanism. In experiments conducted in mice, investigators at Massachusetts General Hospital (MGH) have found that very slow spontaneous vessel pulsations – also known as ‘vasomotion’ – drive the clearance of substances from the brain, indicating that targeting and improving this process may help to prevent or treat amyloid-beta accumulation.
In their study published in Neuron, the researchers injected a fluorescently labeled carbohydrate called dextran into the brains of awake mice, and they conducted imaging tests to follow its clearance. Their experiments revealed that vasomotion was critical for clearing dextran from the brain and stimulating an increase of the amplitude of these vessel pulsations could increase clearance. Also, in mice with cerebral amyloid angiopathy, a condition that causes amyloid-beta to build up in the walls of the brain’s blood vessels, vessel pulsations were hindered and clearance rates were reduced.
“We were able to show for the first time that large dilations and contractions of vessels that happen spontaneously at an ultra-low frequency are a major driving force to clear waste products from the brain,” said lead author Susanne van Veluw, PhD, an investigator in the department of Neurology at MGH. “Our findings highlight the importance of the vasculature in the pathophysiology of Alzheimer’s disease. If we direct therapeutic strategies towards promoting healthy vasculature and therefore improve clearance of amyloid-beta from the brain, we may be able to prevent or delay the onset of Alzheimer’s disease in the future.”
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $1 billion and comprises more than 8,500 researchers working across more than 30 institutes, centers and departments. In August 2019 the MGH was once again named #2 in the nation by U.S. News & World Report in its list of "America’s Best Hospitals."
The researchers found that damage to the heart is driven by a different immune response than the anti-tumor one, suggesting that this serious complication could one day be managed without halting cancer therapy.
Cesar M. Castro, MD, MSc, and Hakho Lee, PhD, are co-corresponding authors of a paper published in Nature Biotechnology, “Amplifying mutational profiling of extracellular vesicle mRNA with SCOPE.”
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) awards the 2024 Gupta Family Endowed Prize for Innovation in ALS Care.
The Sean. M. Healey & AMG Center for ALS at Massachusetts General Hospital through the generosity of Drs. Shelena and Ayeez Lalji, is delighted to announce the 2nd annual Drs. Ayeez and Shelena Lalji & Family Student Scholar for Repair and Regenerative Mechanisms in ALS.
The John and Ashley Ranelli Endowed Scholar in Cancer Innovation will activate funding of promising cancer research, helping to advance critical work in the fight against cancer.
Francisco Flores, PhD, is lead author of a recently published paper in Techniques and Methods; Electrographic Seizures During Low-Current Thalamic Deep Brain Stimulation in Mice
